Kieran O'Kane - 02 Jan 2026 Form 4 Insider Report for BIODESIX INC (BDSX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: BDSX
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:25:20 UTC
Prior SEC filing: 13 Nov 2025
Next SEC filing: 20 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane

Key filing fact

Kieran O'Kane filed Form 4 for BIODESIX INC (BDSX) on 06 Jan 2026.

Key facts

This page summarizes Kieran O'Kane's Form 4 filing for BIODESIX INC (BDSX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 16:25.

Change

Previous filing in this sequence was filed on 13 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001828131 Primary reporting owner

O'Kane Kieran

Relationship: Chief Commercial Officer
Address: 919 WEST DILLON RD, LOUISVILLE
Signature: /s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BDSX transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +27,000
Change %
Price: $0.000000
Shares after: 27,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,000
Exercise price: $6.46
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests in a series of forty-eight successive, substantially equal monthly installments measured from January 2, 2026, generally subject to the Reporting Person's continued service through each applicable vesting date.